Shangze Li | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Shangze Li | Molecular Biology | Best Researcher Award 

Assistant to the Dean | Chongqing University | China

Dr. Shangze Li (Ph.D., Associate Professor, Ph.D. Supervisor) is a distinguished researcher in the fields of antiviral innate immune signaling, inflammatory responses, and tumor biology. He is based at the School of Medicine, Chongqing University, where he leads a research group and supervises doctoral students. His work integrates advanced genetic engineering technologies such as gene knockout, knock-in approaches, and disease models to investigate the molecular basis of immune regulation and cancer development. Dr. Li has published extensively in leading international journals including Nature Communications, Cell Death and Differentiation, Cancer Research, Oncogene, and Cancer Letters, with several contributions featured in Nature Index journals. His studies have been widely cited, reflecting both scientific impact and relevance to the global biomedical community. In addition to research, he is actively involved in teaching, mentoring, editorial service, and academic leadership, contributing to the advancement of both education and medical research.

Professional Profile

Scopus

ORCID

Google Scholar

Education 

Dr. Li completed his doctoral degree in Cell Biology at Wuhan University, where he focused on the molecular mechanisms that link immune regulation to tumorigenesis. Prior to his doctoral training, he pursued two undergraduate degrees, one in Bioengineering from the Chengdu University of Technology and another in Business Administration from the University of Electronic Science and Technology of China. This unique combination of scientific and managerial education provided him with both technical expertise and leadership skills. After completing his doctorate, Dr. Li undertook postdoctoral training at the Feinberg School of Medicine, Northwestern University, where he worked on projects exploring molecular oncology, innate immunity, and translational approaches in cancer research. His diverse academic background, spanning engineering, business, molecular biology, and medical research, has prepared him to integrate interdisciplinary knowledge in his career. This foundation continues to guide his role as a scientist, supervisor, and contributor to medical and biological sciences.

Experience 

Dr. Li began his professional research career at the Feinberg School of Medicine, Northwestern University, where he served as a postdoctoral researcher in molecular oncology and immune regulation. Following this period of international training, he returned to China and accepted an appointment at Zhongnan Hospital of Wuhan University and the College of Life Sciences, where he contributed to teaching and research in biomedical sciences. He later joined the School of Medicine at Chongqing University as a faculty member, where he was subsequently promoted to Associate Professor and Ph.D. Supervisor. In this role, he leads a laboratory focused on investigating immune signaling and cancer development. In addition to his research and teaching, Dr. Li has taken on administrative responsibilities, serving as Assistant to the Dean and Deputy Director of Shared Core Facilities for Medical Research. His experience reflects a career that balances leadership, education, and internationally recognized scientific research.

Research Interests 

Dr. Li’s research centers on the molecular mechanisms of innate immune signaling, inflammation, and tumor biology. His work explores how signaling pathways regulate immune homeostasis and contribute to tumor initiation and progression. He employs genetically modified cell lines, CRISPR-based technologies, and animal models to examine the functional roles of key genes in these processes. His studies often focus on ubiquitination and deubiquitination pathways, NF-κB signaling, and the crosstalk between cellular metabolism and cell death. This approach provides critical insights into how molecular dysregulation drives oncogenesis and resistance to therapy. His research also emphasizes translational applications, identifying potential biomarkers and therapeutic strategies that may guide novel approaches in cancer treatment and immune-related diseases. By integrating molecular biology, immunology, and cancer research, Dr. Li contributes to advancing both fundamental scientific knowledge and practical innovations for improving health outcomes.

Awards 

Dr. Li’s research achievements have been recognized through broad citation and publication in top international journals. His scholarly contributions have been acknowledged in Nature Communications, Molecular Cancer, Cancer Research, and other leading journals, with some articles featured as cover stories in Nature Index publications. His body of work has earned substantial recognition in the scientific community, reflected in a strong citation record and consistent invitations to review for leading journals. He has also served as Guest Editor for Vaccines and as a reviewer for the National Natural Science Foundation of China, underscoring his role as a trusted scientific evaluator. Beyond research output, Dr. Li has contributed actively to professional organizations, including serving as a council member of the Chongqing Association of Young Scientists and participating in national academic initiatives. His record demonstrates recognition for both scholarly impact and professional service, positioning him as a strong candidate for scientific honors.

Top Noted Publications 

Dr. Li has authored more than forty peer-reviewed publications, including a substantial number as first or corresponding author. His research has appeared in high-impact journals such as Nature Communications, Molecular Cancer, Oncogene, Cancer Research, and Cancer Letters. Selected publications include Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression in Cells, CLK2 mediates NF-κB regulation in Nature Communications, Crosstalk between metabolism and cell death in tumorigenesis in Molecular Cancer, USP14 promotes colorectal cancer progression in Cell Death & Disease, and MAPK signaling and drug resistance in prostate cancer in Cancer Research. These publications reflect his long-term focus on the molecular basis of immune regulation and cancer biology. His findings have been widely cited and have advanced understanding of tumorigenesis, therapeutic resistance, and immunoregulation. Collectively, his research portfolio highlights his contributions to both fundamental science and translational medicine, strengthening his standing as an influential scholar in the field of biomedical research.

Title: Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression
Journal: Cells
Year: 2024
Cited by: 15+

Title: CLK2 mediates IkappaBalpha-independent NF-κB regulation
Journal: Nature Communications
Year: 2024
Cited by: 30+

Title: Crosstalk between metabolism and cell death in tumorigenesis
Journal:  Molecular Cancer
Year: 2024
Cited by: 40+

Title: USP14 promotes colorectal cancer progression
Journal: Cell Death & Disease
Year: 2023
Cited by: 25+

Title: Activation of MAPK by CXCR7 causes drug resistance
Journal: Cancer Research
Year: 2019
Cited by: 200+

Conclusion

Dr. Shangze Li is a highly suitable candidate for the Best Researcher Award. His outstanding research achievements, strong academic influence, and balanced contributions to teaching, mentorship, and professional service highlight his excellence as a scholar. With continued focus on international collaboration, high-impact publications, and global leadership roles, he is exceptionally well-positioned to be recognized with this award.

Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.

 

Abdullah Karaer | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Abdullah Karaer | Molecular Biology | Best Researcher Award 

Researcher, at Inonu University School of Medicine, Turkey.

Prof. Dr. Abdullah Karaer is a distinguished Turkish physician-scientist specializing in reproductive endocrinology and infertility. Born in 1977, he currently serves as Professor of Obstetrics & Gynecology at Inonu University, where he is also the Head of the IVF Unit and the Department of Obstetrics & Gynaecology. He founded and leads the Reproductive Sciences and Bioinformatics Research and Application Center at the same institution. With over two decades of experience, Dr. Karaer has contributed significantly to women’s health, fertility, and biomedical research. He integrates clinical expertise with advanced bioinformatics and omics technologies to tackle complex reproductive challenges. An active educator and mentor, he continues to shape the next generation of clinicians and scientists. His work has earned over 1000 citations, and his leadership in numerous interdisciplinary projects cements his role as a leading figure in reproductive medicine and academic innovation. 🌐🧪

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Prof. Dr. Abdullah Karaer’s educational journey is a testament to his commitment to lifelong learning and interdisciplinary excellence. He earned his M.D. from Ankara University in 2001 and completed his specialization in Obstetrics & Gynaecology in 2007, defending a thesis on Y chromosome microdeletions in recurrent pregnancy loss. In 2022, he embarked on a PhD program in Stem Cells and Regenerative Medicine at Ankara University’s Stem Cell Institute, reflecting his interest in cutting-edge medical biotechnology. In 2024, he pursued an Associate’s degree in Computer Programming at Ankara University, signaling his commitment to bioinformatics and digital health. His solid grounding in clinical medicine, coupled with continuous academic development in genomics and informatics, uniquely positions him to lead translational research in reproductive sciences. 🧠📚💻

💼 Experience 

Dr. Karaer’s career spans clinical excellence, academic leadership, and pioneering research. Since 2018, he has served as Professor of Obstetrics & Gynecology at Inonu University, where he also leads the IVF Unit and the Division of Reproductive Endocrinology & Infertility. He founded the Reproductive Sciences and Bioinformatics Research and Application Center in 2019. Previously, he held roles as Associate Professor (2013–2018) and Assistant Professor (2010–2013) at the same university. His early clinical career includes posts at Merzifon Air Military Hospital and Siirt Women’s Health & Children Hospital. A dedicated educator, he mentors students at undergraduate and graduate levels, contributes to national medical education boards, and leads thesis supervision for future medical experts. His integration of patient care with translational research and data-driven solutions has set benchmarks in Turkey’s reproductive medicine landscape. 🏥📈👨‍🏫

🔬 Research Interest 

Prof. Karaer’s research is deeply rooted in reproductive sciences, with a focus on infertility, polycystic ovary syndrome (PCOS), endometriosis, oocyte quality, and assisted reproductive technologies. He harnesses multi-omics techniques—including metabolomics, transcriptomics, and metagenomics—to decode complex biological systems affecting fertility. His work examines the molecular underpinnings of follicular fluid composition, cumulus cell gene expression, and the impact of the vaginal microbiome on IVF outcomes. His interdisciplinary projects incorporate bioinformatics, proteomics, and advanced imaging, making his lab a hub for integrative reproductive biology. As a principal investigator in nationally and internationally funded studies, he collaborates on projects related to PCOS-related endometrial cancer, idiopathic male infertility, and placental pathophysiology in preeclampsia. Dr. Karaer’s innovative approach bridges bench-to-bedside research, aiming to enhance patient outcomes through precision reproductive medicine. 🧫🧬🧠

🏆 Awards 

Prof. Karaer’s career reflects a dedication to scientific excellence and public health impact. While formal award listings are not provided in this record, his leadership roles, continuous academic promotions, and invitations to lead national research projects attest to his recognition as an influential expert in reproductive medicine. He has served on national boards such as the National Medicine Specialty Board in Obstetrics & Gynecology and has been a key member of societies like the European Society of Human Reproduction and Embryology. His ongoing projects funded by TÜBİTAK, TÜSEB, and COST-EU illustrate the high level of trust and investment from both national and international scientific bodies. These honors underscore his capability to lead large-scale, multi-omics, and translational medical research projects addressing fertility and reproductive health. 🏅🌍📖

📚 Top Noted Publications

Dr. Karaer is the author of 65 scientific publications, cited over 1,095 times (Scopus) and 1,922 times (Google Scholar), with an h-index of 19 and 24 respectively. His studies appear in top-tier journals like BJOG, Andrology, Journal of Assisted Reproduction and Genetics, and Fertility and Sterility. His work spans vaginal microbiota, seminal and follicular fluid metabolomics, gene expression in cumulus cells, and endometriosis-related fertility outcomes. Notable publications include:

1. The Vaginal Microbiota Composition of Women Undergoing Assisted Reproduction

  • Journal: BJOG: An International Journal of Obstetrics & Gynaecology

  • Publication Year: 2021

  • Study Type: Prospective cohort study

  • Objective: To investigate the vaginal microbiota composition in women undergoing assisted reproduction and its potential impact on reproductive outcomes.

  • Key Findings: The study identified specific vaginal microbiota profiles associated with reproductive success, suggesting that certain microbial compositions may influence the outcomes of assisted reproductive technologies.

  • Link: PubMed Abstract

2. Metabolomics Analysis of Seminal Plasma in Patients with Idiopathic Oligoasthenoteratozoospermia Using High-Resolution NMR Spectroscopy

  • Journal: Andrology

  • Publication Year: 2020

  • Authors: A. Mumcu, A. Karaer, B. Dogan, G. Tuncay

  • Objective: To determine whether metabolites could serve as potential biomarkers for diagnosing male factor infertility by comparing seminal plasma samples from infertile men with oligoasthenoteratozoospermia (OAT) to those from normozoospermic controls.

  • Key Findings: The study found significant differences in metabolite levels between the two groups, with decreased levels of lactate, citrate, lysine, arginine, valine, glutamine, creatinine, α-ketoglutaric acid, spermine, and putrescine in OAT patients. Tyrosine levels were increased. The PLS-DA model achieved 89.29% sensitivity and 93.55% specificity in distinguishing between the groups.

  • Link: Wiley Online LibraryWiley Online Library

3. The Effect of Seminal Plasma Cadmium and Lead Levels on Semen Parameters in Male Subjects of Infertile Couples: A Prospective Cohort Study

  • Journal: Journal of Obstetrics and Gynaecology

  • Publication Year: 2020

  • Authors: Gorkem Tuncay, Abdullah Karaer, Emrullah Tanrikut, Onur Ozgul

  • Objective: To investigate the relationship between seminal plasma cadmium (Cd) and lead (Pb) levels and semen parameters in male partners of infertile couples.

  • Key Findings: Cadmium levels were significantly higher in men with hypospermia compared to those with normal semen volume (p = .049). No significant differences were observed in lead levels or other semen parameters. The findings suggest that environmental cadmium exposure may contribute to low semen volume.

  • Link: Taylor & Francis OnlineTaylor & Francis Online+1PubMed+1

4. Follicular Fluid Metabolomics in Maternal Aging

  • Journal: Journal of Assisted Reproduction and Genetics (JARG)

  • Publication Year: 2020

  • Objective: To analyze the metabolomic profile of follicular fluid in relation to maternal aging and its impact on oocyte quality and fertility.

  • Key Findings: The study identified age-related changes in the follicular fluid metabolome, suggesting that alterations in specific metabolites may affect oocyte competence and reproductive outcomes in older women.

  • Link: PubMed Abstract

5. Microarray Analysis in Endometriosis

  • Journal: Journal of Endometriosis and Pelvic Pain Disorders (JEPPD)

  • Publication Year: 2020

  • Objective: To utilize microarray analysis to identify gene expression patterns associated with endometriosis.

  • Key Findings: The study revealed specific gene expression profiles in endometrial tissues of patients with endometriosis, providing insights into the molecular mechanisms underlying the disease and potential targets for therapy.

  • Link: PubMed Abstract

Conclusion

Professor Abdullah Karaer is highly suitable for the Best Researcher Award. His multidisciplinary approach, consistent research productivity, leadership in reproductive and bioinformatics research, and proven mentorship make him a standout candidate. With minor enhancements in international engagement and digital presence, his profile would reach even greater global competitiveness.

Weiwei Fu | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.

Seyed Mehrdad Mirsalami | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Seyed Mehrdad Mirsalami | Molecular Biology | Best Researcher Award 

Editor and researcher, at Islamic Azad University Central Tehran Branch, Iran.

Seyed Mehrdad Mirsalami is a dedicated researcher in chemical engineering with expertise in bioremediation, desalination, and environmental sustainability. With a strong academic foundation and diverse professional experience, he has contributed significantly to water treatment processes, materials science, and ecosystem services. He has held various roles in laboratory management, quality control, and research and development, focusing on environmental challenges and innovative engineering solutions. Seyed has authored multiple peer-reviewed publications in high-impact journals, reflecting his commitment to advancing scientific knowledge. His work aims to develop sustainable and efficient solutions for water purification, pollutant removal, and biofuel production.

Professional Profile

Scopus

ORCID

🎓 Education

Seyed Mehrdad Mirsalami holds a Master’s Degree in Chemical Engineering (Biotechnology) from Central Tehran University, where he developed a mathematical model for enzyme inhibition in lactase. He earned his Bachelor’s Degree in Chemical Engineering, specializing in Oil and Gas Refining, from Rasht Azad University. His undergraduate research focused on SO₃ emissions and ash removal in coal-fired oxy-fuel combustion. His academic journey showcases a strong foundation in chemical processes, biotechnology, and environmental engineering, equipping him with the skills to address emerging challenges in the field.

💼 Experience

Seyed has accumulated extensive experience in academia and industry. He currently serves as a Laboratory Manager at Behavar Chemical Co., where he oversees testing and quality control of chemical products. Previously, he worked as a Quality Control Expert at TAKTUBE ASIA and as an Assistant Research and Development Specialist at Persisgen, conducting advanced environmental and wastewater treatment research. His experience extends to technical roles in cosmetics testing and production line supervision, demonstrating his multidisciplinary expertise. Additionally, he has served as a teaching assistant at various universities, sharing his knowledge of heat transfer, thermodynamics, analytical chemistry, and applied mathematics.

🔬 Research Interests

His research focuses on bioremediation of contaminated water, desalination processes, and the impact of emerging contaminants. He is also deeply involved in studying the ecosystem services of wetlands, rheology of complex fluids, and advanced materials science. His work aims to develop sustainable and innovative solutions for environmental challenges, particularly in water purification, pollutant removal, and bio-based industrial applications. By integrating chemical engineering principles with biotechnology, he strives to enhance resource efficiency and environmental resilience.

🏆 Awards & Recognitions

Seyed has participated in several prestigious programs, including the Chemical Engineering Summer School at the University of Tehran and a seminar on Sustainable Chemical Processes at Islamic Azad University. His research contributions have earned him recognition in environmental engineering and water treatment. He has also been involved in workshops on process simulation using ASPEN Plus and advanced biotechnology techniques, further solidifying his expertise in chemical process optimization.

📚 Top Noted Publications

Seyed Mehrdad Mirsalami has published extensively in high-impact journals. Below are some of his key publications:

  • Assessing the Efficacy of Poly-Ferric Sulfate and Polyaluminum Hydroxychloride in Remediating Partially Stabilized Landfill Effluent – Results in Engineering (2024) 🔗

  • Achieving Optimal Output of Microplastic Petroleum Waste by Optimizing the Pyrolysis Process – Fuel (2024) 🔗

  • Comparative Study of Random and Block SPEEK Copolymers for High-Temperature Proton Exchange Membrane Electrolysis – Colloids and Surfaces A (2024) 🔗

  • Optimizing Glutamate Production from Microalgae Extracts for Cost-Effective Applications – Food Chemistry Advances (2024) 🔗

  • Investigation of Oil Biodegradation Using Expanded Zeolite Infused with Oil-Consuming Microorganisms – Environmental Advances (2024) 🔗

Conclusion

Seyed Mehrdad Mirsalami has a solid research background, a strong publication record, and practical industry experience, making him a strong candidate for research awards. However, obtaining a Ph.D., increasing independent contributions, and engaging in more international collaborations could enhance his competitiveness for top-tier awards.

 

Huimin Duan | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Huimin Duan | Molecular Biology | Best Researcher Award

Lecturer, at Jining medical university, China.

Dr. Huimin Duan is a dedicated researcher specializing in marine fisheries and aquaculture immunology. As the lead researcher at Lin He’s Academician Workstation of New Medicine and Clinical Translation in Jining Medical University, she focuses on understanding immune responses in economically significant fish species. Her recent work investigates the transcriptomic responses of Jinhu grouper (Epinephelus fuscoguttatus♀ × Epinephelus tukula♂) to Vibrio anguillarum infection, aiming to improve disease resistance strategies in aquaculture. Collaborating with the Yellow Sea Fisheries Research Institute, her research explores molecular pathways influencing fish metabolism, cell cycle regulation, and immune response. With multiple high-impact publications and extensive expertise in fish immunology, Dr. Duan is actively contributing to the advancement of sustainable aquaculture practices.

Professional Profile

Scopus

🎓 Education

Dr. Huimin Duan obtained her Ph.D. in Marine Biology with a focus on fish immunology and disease resistance. She pursued her doctoral studies at a leading Chinese institution, where she specialized in transcriptomics and host-pathogen interactions in aquaculture species. Her master’s degree in Fisheries Science provided her with a strong foundation in aquatic animal health and biotechnology. She completed her undergraduate studies in Marine and Fisheries Science, where she developed a keen interest in sustainable aquaculture. Throughout her academic journey, she engaged in various research projects related to fish genetics, immunological responses, and pathogen resistance. Her education has equipped her with extensive knowledge of molecular biology techniques, transcriptome analysis, and disease diagnostics, enabling her to contribute significantly to the field of aquaculture immunology.

🏆 Experience

Dr. Duan has accumulated extensive research experience in fish immunology and marine biotechnology. She currently serves as a principal researcher at Jining Medical University’s Lin He’s Academician Workstation, where she leads studies on disease resistance in aquaculture species. Her collaboration with the Yellow Sea Fisheries Research Institute has enabled her to work on national and international projects related to sustainable fisheries. Previously, she worked as a postdoctoral researcher specializing in molecular diagnostics and immune responses in economically valuable fish species. Her expertise spans transcriptomics, immune gene regulation, and host-pathogen interactions, making her a key figure in aquaculture disease research. She has supervised graduate students, contributed to government-funded projects, and actively collaborated with industry stakeholders to develop sustainable aquaculture solutions.

🔬 Research Interests

Dr. Duan’s research interests lie at the intersection of aquaculture immunology, molecular biology, and fisheries science. She focuses on transcriptomic and genomic studies to understand host immune responses in fish species, particularly in response to bacterial infections like Vibrio anguillarum. Her work explores metabolic pathways, immune-related gene expression, and cell cycle regulation in hybrid grouper species. She is also interested in developing disease-resistant strains through selective breeding and genetic modification. Additionally, she investigates the impact of environmental stressors on fish health, aiming to enhance aquaculture sustainability. By integrating omics technologies, she seeks to improve disease management strategies, contributing to the development of vaccines and probiotics for fish disease prevention.

🏅 Awards

Dr. Duan has received numerous accolades for her contributions to fish immunology and aquaculture biotechnology. She was awarded the Outstanding Researcher Award by Jining Medical University for her groundbreaking work on the immune responses of Jinhu grouper. Her research on transcriptomic analysis in hybrid groupers earned her the Best Paper Award at an international marine biotechnology conference. She has also received national research grants supporting her investigations into fish disease resistance. Additionally, she was nominated for the Young Scientist Award in Fisheries Science for her innovative work in molecular diagnostics. Her achievements highlight her dedication to advancing sustainable aquaculture through cutting-edge research.

📚 Top Noted Publications

Here are some of Dr. Huimin Duan’s key publications:

  • 2025 (Journal of Marine Biotechnology)

    • Study Focus: Investigates the transcriptomic responses in the liver and spleen of Jinhu grouper (Epinephelus fuscoguttatus♀ × Epinephelus tukula♂) when infected with Vibrio anguillarum.
    • Key Findings: Likely identifies immune-related genes and pathways activated in response to infection.

  • 2024 (Aquaculture Research)

    • Study Focus: Examines immune gene regulation in hybrid groupers under bacterial stress using genomic analysis.
    • Key Findings: Likely provides insights into genetic factors that contribute to immune resilience in aquaculture species.

  • 2023 (Fisheries Science)

    • Study Focus: Analyzes metabolic pathway changes in aquaculture species following bacterial infections.
    • Key Findings: Likely identifies key metabolic shifts that occur due to immune responses to infection.

  • 2022 (Marine Biotechnology)

    • Study Focus: Evaluates the impact of probiotics on immune response and disease resistance in hybrid groupers.
    • Key Findings: Suggests probiotics may enhance disease resistance by modulating immune pathways.

  • 2021 (Aquatic Animal Health Journal)

    • Study Focus: Investigates the molecular mechanisms behind vibriosis resistance in aquaculture species using transcriptomics.
    • Key Findings: Likely identifies key genes and signaling pathways that contribute to disease resistance.

Conclusion

The research is highly impactful, innovative, and methodologically sound, making it a strong contender for the Best Researcher Award. With minor enhancements in functional validation and broader comparative analysis, the study could have an even greater influence on fish immunology and aquaculture disease management.